Eli Lilly has become the first $1 trillion pharma firm as it cashes in on booming demand for weight-loss drugs.
The US fat jab company hit the milestone when its shares rose 2 per cent to more than $1,060 in trading on Wall Street.
The Mounjaro maker joins the elite club of firms worth trillions, such as tech giants Nvidia, Microsoft and Apple, as well as Elon Musk’s Tesla and Warren Buffett’s Berkshire Hathaway.
Eli Lilly’s stock has jumped 47 per cent in six months, rebounding from a setback in August when trial data on its experimental weight-loss pill orforglipron fell short of expectations.
Boost: Eli Lilly has become the first $1 trillion pharma firm as it cashes in on booming demand for weight-loss drugs
The company has successfully pulled ahead of main rival Novo Nordisk, the Danish maker of Wegovy and Ozempic.
Shares have also surged after last month’s results, with revenues up 54 per cent to £13.4billion in the three months to September – in contrast with Novo Nordisk’s stock, which is down by 52 per cent so far this year.
Investor hopes have also been bolstered as threats of tariffs on pharma imports by US President Donald Trump have receded.
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
Freetrade
Freetrade
Investing Isa now free on basic plan
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
